Media Coverage
Read how VistaGen’s intention to revolutionize mental health medicine is causing a buzz in the media.
Chutes & Ladders—Former Merck R&D chief Perlmutter takes reins at Eikon, applying Nobel-winning tech to drug discovery
To read the full story, subscribe or sign in. Appointments and advancements for May 4, 2021
New data shows strength in VistaGen’s PH94B for SAD
A Potential Benzodiazepine Replacement
Shawn Singh of VistaGen Therapeutics: 5 Ways That Businesses Can Help Promote The Mental Wellness Of Their Employees
VistaGen readies Phase 3 trial of novel, fast-acting neuroactive nasal spray in social anxiety disorder
Local Biotech Firms Poised to Benefit from Rosy Venture Capital Outlook for 2021
CBC Group sets up AffaMed, EverInsight merger, eyes IPO
Complementing Your Psychotherapy
